| 1 | Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroupsBrain, 2022, 145, 1757-1762 | 8.9 | 22 | Citations (PDF) |
| 2 | α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity | 7.7 | 88 | Citations (PDF) |
| 3 | Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases | 3.4 | 13 | Citations (PDF) |
| 4 | Inflammation in dementia with Lewy bodies | 5.2 | 38 | Citations (PDF) |
| 5 | Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations | 13.1 | 8 | Citations (PDF) |
| 6 | Prospective predictors of decline <i>v.</i> stability in mild cognitive impairment with Lewy bodies or Alzheimer's disease | 4.6 | 14 | Citations (PDF) |
| 7 | Cognitive Decline in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease: A Prospective Cohort Study | 1.5 | 22 | Citations (PDF) |
| 8 | Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster‐Randomized Trial | 5.3 | 5 | Citations (PDF) |
| 9 | Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders | 7.9 | 36 | Citations (PDF) |
| 10 | Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture | 16.3 | 221 | Citations (PDF) |
| 11 | Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease | 1.3 | 24 | Citations (PDF) |
| 12 | Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months | 1.3 | 15 | Citations (PDF) |
| 13 | Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders | 7.9 | 36 | Citations (PDF) |
| 14 | Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study | 7.9 | 138 | Citations (PDF) |
| 15 | Dementia in the older population is associated with neocortex content of serum amyloid P component | 3.8 | 6 | Citations (PDF) |
| 16 | What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons | 3.4 | 169 | Citations (PDF) |
| 17 | New evidence on the management of Lewy body dementia | 19.1 | 210 | Citations (PDF) |
| 18 | Cholinergic muscarinic M1/M4 receptor networks in dementia with Lewy bodies | 3.8 | 12 | Citations (PDF) |
| 19 | Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms | 1.0 | 11 | Citations (PDF) |
| 20 | The challenges of <scp>COVID</scp>‐19 for people with dementia with Lewy bodies and family caregivers | 2.4 | 23 | Citations (PDF) |
| 21 | Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson’s and Lewy body diseases | 0.7 | 0 | Citations (PDF) |
| 22 | Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson’s and Lewy body diseases | 0.7 | 1 | Citations (PDF) |
| 23 | Clinical diagnosis of Lewy body dementia | 1.0 | 36 | Citations (PDF) |
| 24 | Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study | 3.4 | 23 | Citations (PDF) |
| 25 | Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management | 2.0 | 83 | Citations (PDF) |
| 26 | Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial | 1.6 | 37 | Citations (PDF) |
| 27 | Research criteria for the diagnosis of prodromal dementia with Lewy bodies | 1.3 | 456 | Citations (PDF) |
| 28 | Dementia with Lewy bodies: an update and outlook | 14.2 | 244 | Citations (PDF) |
| 29 | Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial | 6.7 | 24 | Citations (PDF) |
| 30 | Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases | 3.4 | 34 | Citations (PDF) |
| 31 | Prevalence and severity of symptoms suggestive of gastroparesis in prodromal dementia with Lewy bodies | 2.4 | 4 | Citations (PDF) |
| 32 | Pathological Changes to the Subcortical Visual System and its Relationship to Visual Hallucinations in Dementia with Lewy Bodies | 4.1 | 16 | Citations (PDF) |
| 33 | Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms | 3.4 | 28 | Citations (PDF) |
| 34 | Extravascular fibrinogen in the white matter of Alzheimer’s disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer’s disease | 4.7 | 27 | Citations (PDF) |
| 35 | Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies | 4.6 | 57 | Citations (PDF) |
| 36 | Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment | 5.3 | 66 | Citations (PDF) |
| 37 | Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies | 5.3 | 27 | Citations (PDF) |
| 38 | Author response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium | 1.3 | 15 | Citations (PDF) |
| 39 | Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies | 4.6 | 73 | Citations (PDF) |
| 40 | Clinical prevalence of Lewy body dementia | 6.7 | 156 | Citations (PDF) |
| 41 | Non-pharmacological interventions for Lewy body dementia: a systematic review | 4.6 | 48 | Citations (PDF) |
| 42 | A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriersBrain, 2018, 141, 2895-2907 | 8.9 | 40 | Citations (PDF) |
| 43 | Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The <scp>DIAMOND</scp> Lewy study | 2.4 | 32 | Citations (PDF) |
| 44 | The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target | 8.9 | 23 | Citations (PDF) |
| 45 | Donald Eccleston, FRCPsych, PhD, DSc | 1.1 | 0 | Citations (PDF) |
| 46 | Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease | 2.7 | 33 | Citations (PDF) |
| 47 | Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies | 5.3 | 35 | Citations (PDF) |
| 48 | Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology | 5.8 | 183 | Citations (PDF) |
| 49 | Neuronal Loss and Α-Synuclein Pathology in the Superior Colliculus and Its Relationship to Visual Hallucinations in Dementia with Lewy Bodies | 1.5 | 30 | Citations (PDF) |
| 50 | Diagnosis and management of dementia with Lewy bodies | 1.3 | 2,992 | Citations (PDF) |
| 51 | Symptoms associated with Lewy body disease in mild cognitive impairment | 2.4 | 35 | Citations (PDF) |
| 52 | Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort | 2.7 | 68 | Citations (PDF) |
| 53 | Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts | 3.6 | 20 | Citations (PDF) |
| 54 | Autopsy validation of
<sup>123</sup>
I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB | 1.3 | 135 | Citations (PDF) |
| 55 | Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study | 2.4 | 41 | Citations (PDF) |
| 56 | Author response: Autopsy validation of
<sup>123</sup>
I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB | 1.3 | 6 | Citations (PDF) |
| 57 | Transcranial direct current stimulation in Parkinson's disease dementia: A randomised double-blind crossover trial | 1.6 | 8 | Citations (PDF) |
| 58 | Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease | 7.9 | 187 | Citations (PDF) |
| 59 | Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial) | 2.4 | 49 | Citations (PDF) |
| 60 | TDP‐43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing | 4.7 | 179 | Citations (PDF) |
| 61 | Clinical Diagnostic Criteria for Dementia with Lewy Bodies 2017, , 59-71 | | 4 | Citations (PDF) |
| 62 | Regional levels of physiological α-synuclein are directly associated with Lewy body pathology | 7.9 | 31 | Citations (PDF) |
| 63 | Cholinergic and perfusion brain networks in Parkinson disease dementia | 1.3 | 43 | Citations (PDF) |
| 64 | Changes to the lateral geniculate nucleus in <scp>A</scp>lzheimer's disease but not dementia with <scp>L</scp>ewy bodies | 3.4 | 24 | Citations (PDF) |
| 65 | Support and information needs following a diagnosis of dementia with Lewy bodies | 1.0 | 32 | Citations (PDF) |
| 66 | Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations | 5.1 | 61 | Citations (PDF) |
| 67 | Arguing against the proposed definition changes of PD | 5.3 | 56 | Citations (PDF) |
| 68 | Depressive symptoms are associated with daytime sleepiness and subjective sleep quality in dementia with Lewy bodies | 2.4 | 14 | Citations (PDF) |
| 69 | Revisiting DLB Diagnosis | 2.8 | 92 | Citations (PDF) |
| 70 | Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease | 6.7 | 75 | Citations (PDF) |
| 71 | Visual Hallucinations in Eye Disease and Lewy Body Disease | 1.5 | 22 | Citations (PDF) |
| 72 | Unexplained Delirium, Atypical Dementia, and Prodromal DLB 2016, , 3-6 | | 0 | Citations (PDF) |
| 73 | Accumulation of dipeptide repeat proteins predates that of <scp>TDP</scp>‐43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in <scp><i>C9ORF72</i></scp> gene | 3.4 | 58 | Citations (PDF) |
| 74 | Cortical Thickness in Dementia with Lewy Bodies and Alzheimer's Disease: A Comparison of Prodromal and Dementia Stages | 2.5 | 91 | Citations (PDF) |
| 75 | Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences | 2.4 | 39 | Citations (PDF) |
| 76 | Patient and Informant Views on Visual Hallucinations in Parkinson Disease | 1.5 | 6 | Citations (PDF) |
| 77 | Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis | 10.5 | 207 | Citations (PDF) |
| 78 | Clinicians' ability to diagnose dementia with Lewy bodies is not affected by β-amyloid load | 1.3 | 46 | Citations (PDF) |
| 79 | Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses | 19.1 | 129 | Citations (PDF) |
| 80 | Regional covariance of muscarinic acetylcholine receptors in Alzheimer’s disease using (R, R) [123I]-QNB SPECT | 3.4 | 10 | Citations (PDF) |
| 81 | Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials | 2.0 | 34 | Citations (PDF) |
| 82 | The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis | 6.7 | 181 | Citations (PDF) |
| 83 | The Dementia Cognitive Fluctuation Scale, a New Psychometric Test for Clinicians to Identify Cognitive Fluctuations in People with Dementia | 1.5 | 59 | Citations (PDF) |
| 84 | Visual complaints and visual hallucinations in Parkinson's disease | 2.4 | 76 | Citations (PDF) |
| 85 | Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using <sup>123</sup>I-Ioflupane Injection (DaTscan) Imaging | 6.6 | 14 | Citations (PDF) |
| 86 | Frontotemporal dementia and its subtypes: a genome-wide association study | 19.1 | 282 | Citations (PDF) |
| 87 | How dementia and neurodegenerative disease clinical research networks have enhanced research delivery in England | 0.4 | 1 | Citations (PDF) |
| 88 | Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms | 2.4 | 85 | Citations (PDF) |
| 89 | Distinct cognitive phenotypes in Alzheimer's disease in older people | 1.0 | 8 | Citations (PDF) |
| 90 | Elderly Individuals With FTLD | 14.3 | 4 | Citations (PDF) |
| 91 | Cognitive Decline and Dementia Risk in Older Adults With Psychotic Symptoms: A Prospective Cohort Study | 1.5 | 43 | Citations (PDF) |
| 92 | Synaptic Proteins and Choline Acetyltransferase Loss in Visual Cortex in Dementia With Lewy Bodies | 1.9 | 45 | Citations (PDF) |
| 93 | Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review | 2.0 | 110 | Citations (PDF) |
| 94 | Covariant perfusion patterns provide clues to the origin of cognitive fluctuations and attentional dysfunction in Dementia with Lewy bodies | 1.0 | 23 | Citations (PDF) |
| 95 | Multivariate Spatial Covariance Analysis of <sup>99M</sup>Tc-Exametazime SPECT Images in Dementia with Lewy Bodies and Alzheimer'S Disease: Utility in Differential Diagnosis | 4.9 | 16 | Citations (PDF) |
| 96 | The assessment of cognition in visually impaired older adults | 1.8 | 34 | Citations (PDF) |
| 97 | A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies | 14.3 | 360 | Citations (PDF) |
| 98 | Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias | 3.6 | 3 | Citations (PDF) |
| 99 | Neuropathological Profile of Mild Cognitive Impairment From a Population Perspective | 1.5 | 15 | Citations (PDF) |
| 100 | Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study | 2.0 | 30 | Citations (PDF) |
| 101 | Relationship Between Mitochondria and α-Synuclein | 6.8 | 43 | Citations (PDF) |
| 102 | Alzheimer and Vascular Neuropathological Changes Associated with Different Cognitive States in a Non-Demented Sample | 2.7 | 32 | Citations (PDF) |
| 103 | Visual cortex in dementia with Lewy bodies: Magnetic resonance
imaging study | 2.3 | 73 | Citations (PDF) |
| 104 | Glucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease | 4.0 | 59 | Citations (PDF) |
| 105 | Supporting clinical research in the NHS in England: the National Institute for Health Research Dementias and Neurodegenerative Diseases Research Network | 6.7 | 8 | Citations (PDF) |
| 106 | Impact of Less Common and “Disregarded” Neurodegenerative Pathologies on Dementia Burden in a Population-Based Cohort | 2.7 | 29 | Citations (PDF) |
| 107 | Frontotemporal Dementia in Elderly Individuals | 6.8 | 46 | Citations (PDF) |
| 108 | Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease | 25.5 | 615 | Citations (PDF) |
| 109 | Plasma homocysteine and cognitive decline in older hypertensive subjects | 1.0 | 21 | Citations (PDF) |
| 110 | Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study | 2.3 | 55 | Citations (PDF) |
| 111 | Determining the minimum clinically important differences for outcomes in the DOMINO trial | 2.4 | 123 | Citations (PDF) |
| 112 | Who will be eligible? An investigation of the dementia population eligible for cholinesterase treatment following the change in NICE guidance | 2.4 | 2 | Citations (PDF) |
| 113 | Adjunct treatment with levodopa in a patient with dementia with Lewy bodies, delusions and severe neuroleptic hypersensitivity syndrome: some comments | 1.0 | 1 | Citations (PDF) |
| 114 | Covariance 99mTc-Exametazime SPECT Patterns in Alzheimer’s Disease and Dementia with Lewy Bodies: Utility in Differential Diagnosis | 2.8 | 17 | Citations (PDF) |
| 115 | Education, the brain and dementia: neuroprotection or compensation?Brain, 2010, 133, 2210-2216 | 8.9 | 296 | Citations (PDF) |
| 116 | Nicotinic 123I-5IA-85380 Single Photon Emission Computed Tomography as a Predictor of Cognitive Progression in Alzheimer's Disease and Dementia With Lewy Bodies | 1.5 | 24 | Citations (PDF) |
| 117 | Optimizing Mild Cognitive Impairment for Discriminating Dementia Risk in the General Older Population | 1.5 | 36 | Citations (PDF) |
| 118 | Pathological correlates of frontotemporal lobar degeneration in the elderly | 7.9 | 70 | Citations (PDF) |
| 119 | Diagnostic accuracy of <sup>123</sup>I-FP-CIT SPECT in possible dementia with Lewy bodies | 2.3 | 125 | Citations (PDF) |
| 120 | Epidemiological Pathology of Dementia: Attributable-Risks at Death in the Medical Research Council Cognitive Function and Ageing Study | 8.1 | 224 | Citations (PDF) |
| 121 | Single‐cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene | 6.6 | 51 | Citations (PDF) |
| 122 | Levodopa use and sleep in patients with dementia with Lewy bodies | 5.3 | 10 | Citations (PDF) |
| 123 | Prevalence, correlates and course of behavioural and
psychological symptoms of dementia in the population | 2.3 | 298 | Citations (PDF) |
| 124 | TOP CITED PAPERS IN INTERNATIONAL PSYCHOGERIATRICS: 1. LONG-TERM USE OF RIVASTIGMINE IN PATIENTS WITH DEMENTIA WITH LEWY BODIES: AN OPEN-LABEL TRIAL | 1.0 | 2 | Citations (PDF) |
| 125 | Commentary: DLB and PDD: the same or different? Is there a debate? | 1.0 | 20 | Citations (PDF) |
| 126 | Mild cognitive impairment in the older population: Who is missed and does it matter? | 2.4 | 39 | Citations (PDF) |
| 127 | Two‐Year Progression from Mild Cognitive Impairment to Dementia: To What Extent Do Different Definitions Agree? | 2.8 | 185 | Citations (PDF) |
| 128 | Dementia with Lewy bodies | 0.4 | 0 | Citations (PDF) |
| 129 | Nicotinic α4β2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations | 4.8 | 50 | Citations (PDF) |
| 130 | Clinical aspects of dementia with Lewy bodies | 0.0 | 4 | Citations (PDF) |
| 131 | What explains variations in the clinical use of mild cognitive impairment (MCI) as a diagnostic category? | 1.0 | 18 | Citations (PDF) |
| 132 | A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies | 1.0 | 57 | Citations (PDF) |
| 133 | Cortical Lewy body disease: dementia with Lewy bodies and Parkinson's disease with dementia 2008, , 293-320 | | 0 | Citations (PDF) |
| 134 | Dementia with Lewy bodies | 2.3 | 1 | Citations (PDF) |
| 135 | Operationalisation of Mild Cognitive Impairment: A Graphical Approach | 8.1 | 54 | Citations (PDF) |
| 136 | Dementia with Lewy Bodies | 2.0 | 77 | Citations (PDF) |
| 137 | Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy | 2.0 | 233 | Citations (PDF) |
| 138 | Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies | 2.0 | 12 | Citations (PDF) |
| 139 | Chapter 9 Dementia with Lewy Bodies and Parkinson's Disease Dementia | 0.0 | 1 | Citations (PDF) |
| 140 | Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia | 2.0 | 22 | Citations (PDF) |
| 141 | Dementia with Lewy bodies | 0.0 | 21 | Citations (PDF) |
| 142 | Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease | 2.4 | 98 | Citations (PDF) |
| 143 | Reaching the population with dementia drugs: what are the challenges? | 2.4 | 20 | Citations (PDF) |
| 144 | Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis | 2.4 | 38 | Citations (PDF) |
| 145 | Clinical diagnostic criteria for dementia associated with Parkinson's disease | 5.3 | 2,415 | Citations (PDF) |
| 146 | Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force | 5.3 | 849 | Citations (PDF) |
| 147 | Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline | 1.8 | 10 | Citations (PDF) |
| 148 | A Comparison of Computerized and Pencil‐and‐Paper Tasks in Assessing Cognitive Function in Community‐Dwelling Older People in the Newcastle 85+ Pilot Study | 2.8 | 61 | Citations (PDF) |
| 149 | Early Cognitive Change in the General Population: How Do Different Definitions Work? | 2.8 | 101 | Citations (PDF) |
| 150 | The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts | 5.2 | 216 | Citations (PDF) |
| 151 | Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study | 19.1 | 610 | Citations (PDF) |
| 152 | Muscarinic acetylcholine receptor status in Alzheimer’s disease assessed using (R, R) 123I-QNB SPECT | 3.4 | 30 | Citations (PDF) |
| 153 | Has the management of Alzheimer's disease changed over the past 100 years? | 35.3 | 8 | Citations (PDF) |
| 154 | In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson’s disease dementia | 4.8 | 53 | Citations (PDF) |
| 155 | Characteristics of Visual Hallucinations in Parkinson Disease Dementia and Dementia With Lewy Bodies | 1.5 | 140 | Citations (PDF) |
| 156 | More Severe Functional Impairment in Dementia With Lewy Bodies Than Alzheimer Disease Is Related to Extrapyramidal Motor Dysfunction | 1.5 | 62 | Citations (PDF) |
| 157 | Progression of White Matter Hyperintensities in Alzheimer Disease, Dementia With Lewy Bodies, and Parkinson Disease Dementia: A Comparison With Normal Aging | 1.5 | 94 | Citations (PDF) |
| 158 | Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism | 3.4 | 57 | Citations (PDF) |
| 159 | Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop | 2.7 | 383 | Citations (PDF) |
| 160 | Pathophysiology of synuclein aggregation in Lewy body disease | 4.6 | 64 | Citations (PDF) |
| 161 | Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies | 5.2 | 54 | Citations (PDF) |
| 162 | Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation | 5.2 | 100 | Citations (PDF) |
| 163 | Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop? | 2.4 | 11 | Citations (PDF) |
| 164 | Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease | 5.3 | 264 | Citations (PDF) |
| 165 | Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology | 5.8 | 124 | Citations (PDF) |
| 166 | Behavioural changes and psychological symptoms in dementia disorders | 19.1 | 178 | Citations (PDF) |
| 167 | Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies | 1.9 | 53 | Citations (PDF) |
| 168 | Dementia with Lewy bodies | 0.4 | 0 | Citations (PDF) |
| 169 | A comparison of the efficacy of donepezil in Parkinson's disease with Dementia and Dementia with Lewy bodies | 2.4 | 82 | Citations (PDF) |
| 170 | Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme | 1.8 | 34 | Citations (PDF) |
| 171 | APOA1 polymorphism influences risk for early-onset nonfamiliar AD | 6.6 | 60 | Citations (PDF) |
| 172 | How to diagnose dementia with Lewy bodies: State of the art | 5.3 | 281 | Citations (PDF) |
| 173 | Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging | 5.3 | 87 | Citations (PDF) |
| 174 | Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT | 5.4 | 77 | Citations (PDF) |
| 175 | Still PADing along: Perception and attention remain key factors in understanding complex visual hallucinations | 0.9 | 1 | Citations (PDF) |
| 176 | Commentary | 1.0 | 5 | Citations (PDF) |
| 177 | Clinical Diagnosis of Dementia With Lewy Bodies 2005, , 361-373 | | 1 | Citations (PDF) |
| 178 | Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies | 2.4 | 32 | Citations (PDF) |
| 179 | Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodiesBrain, 2005, 128, 1267-1276 | 8.9 | 194 | Citations (PDF) |
| 180 | Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies | 2.3 | 60 | Citations (PDF) |
| 181 | Why people see things that are not there: A novel Perception and Attention Deficit model for recurrent complex visual hallucinations | 0.9 | 414 | Citations (PDF) |
| 182 | Dementia with Lewy bodies 2005, , 603-614 | | 2 | Citations (PDF) |
| 183 | Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controlsBrain, 2004, 127, 791-800 | 8.9 | 526 | Citations (PDF) |
| 184 | Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies | 2.8 | 141 | Citations (PDF) |
| 185 | Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies | 6.8 | 287 | Citations (PDF) |
| 186 | A Longitudinal Study of Hippocampal Volume, Cortisol Levels, and Cognition in Older Depressed Subjects | 10.5 | 327 | Citations (PDF) |
| 187 | Dementia with Lewy bodies | 19.1 | 608 | Citations (PDF) |
| 188 | Dementia in Parkinson's disease: common and treatable | 19.1 | 6 | Citations (PDF) |
| 189 | What's new in… Psychiatry: dementia with Lewy bodies | 0.4 | 1 | Citations (PDF) |
| 190 | Involvement of α6/α3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [125I]-α-conotoxin MII binding in the thalamus and striatum. | 1.9 | 48 | Citations (PDF) |
| 191 | Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer's disease using cortical pattern matching: diagnosis and gender effects | 4.8 | 86 | Citations (PDF) |
| 192 | The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease | 4.8 | 52 | Citations (PDF) |
| 193 | Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy-Confirmed Dementia With Lewy Bodies | 10.5 | 115 | Citations (PDF) |
| 194 | Dementia with Lewy bodies and other difficult diagnoses | 1.0 | 8 | Citations (PDF) |
| 195 | Dementia with Lewy bodies | 5.6 | 57 | Citations (PDF) |
| 196 | What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia | 2.4 | 112 | Citations (PDF) |
| 197 | Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross‐sectional comparative study | 5.3 | 137 | Citations (PDF) |
| 198 | SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders | 5.3 | 893 | Citations (PDF) |
| 199 | Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease | 5.3 | 62 | Citations (PDF) |
| 200 | Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions | 1.9 | 79 | Citations (PDF) |
| 201 | Effects of Hypertension on Attention, Memory, and Executive Function in Older Adults. | 3.0 | 89 | Citations (PDF) |
| 202 | Regulation of attention and response to therapy in dementia by butyrylcholinesterase | 7.7 | 76 | Citations (PDF) |
| 203 | Dementia with Lewy bodies | 1.3 | 21 | Citations (PDF) |
| 204 | Dementia with Lewy bodies | 2.4 | 113 | Citations (PDF) |
| 205 | Dementia with Lewy bodies | 2.3 | 157 | Citations (PDF) |
| 206 | Dementia with Lewy bodies | 3.3 | 18 | Citations (PDF) |
| 207 | Old age psychiatry | 2.3 | 5 | Citations (PDF) |
| 208 | Galantamine for vascular dementia | 19.1 | 3 | Citations (PDF) |
| 209 | A comparison of 99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping | 5.4 | 150 | Citations (PDF) |
| 210 | Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex | 2.1 | 55 | Citations (PDF) |
| 211 | Cholinergic and Monoaminergic Correlates of Clinical Symptoms in Dementia with Lewy Bodies | 0.0 | 0 | Citations (PDF) |
| 212 | Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies | 1.9 | 34 | Citations (PDF) |
| 213 | Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease | 6.8 | 152 | Citations (PDF) |
| 214 | Comparison of Extrapyramidal Signs in Dementia With Lewy Bodies and Parkinson's Disease | 2.5 | 68 | Citations (PDF) |
| 215 | The characterisation and impact of ‘fluctuating’ cognition in dementia with Lewy bodies and Alzheimer's disease | 2.4 | 43 | Citations (PDF) |
| 216 | A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia | 2.4 | 304 | Citations (PDF) |
| 217 | How do memory clinics compare with traditional old age psychiatry services? | 2.4 | 41 | Citations (PDF) |
| 218 | Dementia with Lewy Bodies 2001, , 180-186 | | 1 | Citations (PDF) |
| 219 | Dementia with Lewy Bodies: Clinical Management 2001, , 175-179 | | 0 | Citations (PDF) |
| 220 | The Impact of Metrifonate Therapy on Caregivers of Patients with Alzheimer's Disease: Results from the MALT Clinical Trial | 2.8 | 17 | Citations (PDF) |
| 221 | Delusions associated with elevated muscarinic binding in dementia with Lewy bodies | 6.6 | 150 | Citations (PDF) |
| 222 | Dementia with Lewy bodies: findings from an international multicentre study | 2.4 | 87 | Citations (PDF) |
| 223 | Neurocardiovascular Instability, Hypotensive Episodes, and MRI Lesions in Neurodegenerative Dementia | 4.5 | 65 | Citations (PDF) |
| 224 | Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases | 4.4 | 163 | Citations (PDF) |
| 225 | Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study | 35.3 | 1,040 | Citations (PDF) |
| 226 | Profiling conversation in Parkinson's disease with cognitive impairment | 2.5 | 17 | Citations (PDF) |
| 227 | Dementia with Lewy Bodies | 2.7 | 26 | Citations (PDF) |
| 228 | A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study | 2.4 | 43 | Citations (PDF) |
| 229 | Diagnosing dementia with Lewy bodies | 35.3 | 65 | Citations (PDF) |
| 230 | Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia | 4.0 | 213 | Citations (PDF) |
| 231 | Nigrostriatal dopaminergic activities in dementia with lewy bodies in relation to neuroleptic sensitivity: comparisons with parkinson’s disease | 1.7 | 66 | Citations (PDF) |
| 232 | A prospective study of dementia with Lewy bodies | 1.8 | 21 | Citations (PDF) |
| 233 | A Detailed Phenomenological Comparison of Complex Visual Hallucinations in Dementia With Lewy Bodies and Alzheimer's Disease | 1.0 | 58 | Citations (PDF) |
| 234 | HLA-DR antigens associated with major genetic risk for late-onset Alzheimerʼs disease | 1.5 | 53 | Citations (PDF) |
| 235 | No association between an intronic polymorphism in the presenilin-1 gene and Alzheimer's disease | 1.9 | 15 | Citations (PDF) |
| 236 | Neuropsychological aspects of Lewy body dementia 1996, , 99-113 | | 27 | Citations (PDF) |
| 237 | The neuroanatomical basis of cognitive deficits in Lewy body dementia 1996, , 114-131 | | 0 | Citations (PDF) |
| 238 | Pathological significance of Lewy bodies in dementia 1996, , 195-203 | | 11 | Citations (PDF) |
| 239 | What is the neuropathological basis of dementia associated with Lewy bodies? 1996, , 212-223 | | 15 | Citations (PDF) |
| 240 | Dementia with Lewy bodies: relationships to Parkinson's and Alzheimer's diseases 1996, , 268-286 | | 14 | Citations (PDF) |
| 241 | Management of the noncognitive symptoms of Lewy body dementia 1996, , 381-396 | | 2 | Citations (PDF) |
| 242 | Altered consciousness and transmitter signalling in Lewy body dementia 1996, , 397-413 | | 12 | Citations (PDF) |
| 243 | Cholinergic therapy and Lewy body dementia 1996, , 414-424 | | 2 | Citations (PDF) |
| 244 | Clinical heterogeneity in dementia: responders to cholinergic therapy 1996, , 425-438 | | 0 | Citations (PDF) |
| 245 | Tacrine and symptomatic treatment in Lewy body dementia 1996, , 439-448 | | 5 | Citations (PDF) |
| 246 | Neurotrophins and the cholinergic system in dementia 1996, , 468-476 | | 0 | Citations (PDF) |
| 247 | KEY PAPERS IN GERIATRIC PSYCHIATRY. SERIES EDITOR: ALISTAIR BURNS Correlation of Cholinergic Abnormalities with Senile Plaques and Mental Test Scores in Senile Dementia. E. Perry, B. Tomlinson, G. Blessed, K. Bergmann, P. Gibson and R. Perry,British Medical Journal (1978)2, 1457-59. | 2.4 | 4 | Citations (PDF) |
| 248 | Discharge patterns from a psychogeriatric inpatient unit | 2.4 | 3 | Citations (PDF) |
| 249 | Clinical, Pathological and Neurochemical Characteristics of Lewy Body Dementia | 0.0 | 0 | Citations (PDF) |
| 250 | Lewy bodies and Alzheimer's disease | 2.3 | 4 | Citations (PDF) |
| 251 | Gastrointestinal Absorption of Aluminium in Alzheimer's Disease: Response to Aluminium Citrate | 1.8 | 65 | Citations (PDF) |
| 252 | Psychiatric Tutor—Rumour or Reality? | 0.0 | 0 | Citations (PDF) |
